The market for personalized medicine can be segmented on the basis of therapeutic area, end user, application, technology, and region.
By Technology: Pharmacogenomics, metabolomics, pharmacogenetics, stem cell therapy, pharmacodynamics, pharmacoproteomics, pharmacokinetics, and point of care.
By Region: North America, Europe, Asia Pacific, South America and the Middle East and Africa.
The key players of the global personalized medicine market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Qiagen, AstraZeneca Plc., Vertex Pharmaceuticals Incorporated, Pfizer Inc., Roche Holding AG, BD (Becton Dickinson & Co.), Merck & Co. Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc., and others.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.